Correlation between Immunologic Responses to a Recombinant Glycoprotein 120 Vaccine and Incidence of HIV‐1 Infection in a Phase 3 HIV‐1 Preventive Vaccine Trial | Zendy

Peter B. Gilbert | Zendy; Michael Peterson | Zendy; Dean Follmann | Zendy; Michael G. Hudgens | Zendy; Donald P. Francis | Zendy; Marc Gurwith | Zendy; William L. Heyward | Zendy; David V. Jobes | Zendy; Vladimir Popovic | Zendy; Steven G. Self | Zendy; Faruk Sinangil | Zendy; Donald S. Burke | Zendy; Phillip W. Berman | Zendy

Open Access

Correlation between Immunologic Responses to a Recombinant Glycoprotein 120 Vaccine and Incidence of HIV‐1 Infection in a Phase 3 HIV‐1 Preventive Vaccine Trial

Author(s) -

Peter B. Gilbert,

Michael Peterson,

Dean Follmann,

Michael G. Hudgens,

Donald P. Francis,

Marc Gurwith,

William L. Heyward,

David V. Jobes,

Vladimir Popovic,

Steven G. Self,

Faruk Sinangil,

Donald S. Burke,

Phillip W. Berman

Publication year - 2005

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/428405

Subject(s) - immunology , vaccine trial , incidence (geometry) , antibody , hiv vaccine , medicine , cohort , virology , lentivirus , placebo , pre exposure prophylaxis , antibody titer , immune system , relative risk , titer , viral disease , confidence interval , human immunodeficiency virus (hiv) , men who have sex with men , physics , optics , alternative medicine , syphilis , pathology

An objective of the first efficacy trial of a candidate vaccine containing recombinant human immunodeficiency virus (HIV) type 1 envelope glycoprotein 120 (rgp120) antigens was to assess correlations between antibody responses to rgp120 and the incidence of HIV-1 infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research